|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 117.60 INR | -2.00% |
|
-6.26% | +63.58% |
| 05-21 | Dubai Investments says Globalpharma signs 7 strategic MoUs | RE |
| 05-20 | ZIM Laboratories Limited, Q4 2026 Earnings Call, May 20, 2026 |
Company Valuation: ZIM Laboratories Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,178 | 2,596 | 3,528 | 4,653 | 3,908 | 3,203 |
| Change | - | 120.48% | 35.88% | 31.91% | -16.02% | -18.03% |
| Enterprise Value (EV) 1 | 1,987 | 3,095 | 4,085 | 5,672 | 5,065 | 4,066 |
| Change | - | 55.76% | 31.98% | 38.85% | -10.7% | -19.73% |
| P/E | 16.1x | 17.8x | 14.5x | 27x | 32.1x | 50.3x |
| PBR | 0.73x | 1.48x | 1.76x | 1.95x | 1.55x | 1.08x |
| PEG | - | 0.2x | 0.2x | -0.9x | -1.1x | -1x |
| Capitalization / Revenue | 0.38x | 0.78x | 0.89x | 1.27x | 1.03x | 0.86x |
| EV / Revenue | 0.65x | 0.93x | 1.02x | 1.54x | 1.34x | 1.09x |
| EV / EBITDA | 5.22x | 7.98x | 8.19x | 14.5x | 12.8x | 16.4x |
| EV / EBIT | 8.26x | 12.4x | 11.6x | 22.1x | 20.6x | 39.5x |
| EV / FCF | 18.5x | 12.8x | -29.3x | -8.48x | -30.4x | -26.5x |
| FCF Yield | 5.41% | 7.81% | -3.41% | -11.8% | -3.29% | -3.78% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 1.5 | 2.986 | 5.01 | 3.539 | 2.497 | 1.19 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,073 | 3,335 | 3,986 | 3,675 | 3,791 | 3,744 |
| EBITDA 1 | 381 | 387.9 | 499 | 390.6 | 395.6 | 248.4 |
| EBIT 1 | 240.6 | 250.3 | 352.6 | 256.7 | 245.7 | 103 |
| Net income 1 | 73.18 | 145.5 | 244.3 | 172.5 | 121.7 | 58.38 |
| Net Debt 1 | 809.6 | 498.9 | 557.4 | 1,019 | 1,158 | 863.1 |
| Reference price 2 | 24.17 | 53.28 | 72.40 | 95.50 | 80.20 | 59.87 |
| Nbr of stocks (in thousands) | 48,726 | 48,726 | 48,726 | 48,726 | 48,726 | 53,500 |
| Announcement Date | 9/8/21 | 8/26/22 | 6/16/23 | 6/5/24 | 6/3/25 | 6/5/26 |
1INR in Million2INR
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 66.73M | |
| 35.57x | 6.72x | 23.2x | 0.82% | 48.36B | |
| 18.36x | 2.08x | 9.81x | 1.3% | 35.8B | |
| 27.36x | 3.33x | 17.24x | 0.9% | 11.83B | |
| 26.28x | 3.88x | 15.8x | 0.6% | 11.48B | |
| 19.15x | 3.35x | 12.02x | 3.48% | 9.01B | |
| 16.13x | 2.08x | 6.99x | 3.22% | 6.99B | |
| 8.12x | 1.9x | 4.97x | 5.34% | 6.7B | |
| 33.27x | 3.78x | 16.1x | 0.24% | 6.42B | |
| Average | 23.03x | 3.39x | 13.27x | 1.99% | 15.19B | |
| Weighted average by Cap. | 26.04x | 4.14x | 15.76x | 1.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ZIMLAB Stock
- Valuation ZIM Laboratories Limited
Select your edition
All financial news and data tailored to specific country editions
